Purpose: Measurement variance affects the clinical effectiveness of PET-based measurement as a semiquantitative imaging biomarker for cancer response in individual patients and for planning clinical trials. In this study, we measured test-retest reproducibility of SUV measurements under clinical practice conditions and recorded recognized deviations from protocol compliance. Methods: Instrument performance calibration, display, and analyses conformed to manufacture recommendations. Baseline clinical 18 F-FDG PET/CT examinations were performed and then repeated at 1 to 7 days. Intended scan initiation uptake period was to repeat the examinations at the same time for each study after injection of 12 mCi FDG tracer. Avidity of uptake was measured in 62 tumors in 21 patients as SUV for maximum voxel (SUV max ) and for a mean of sampled tumor voxels (SUV mean ). Results: The range of SUV max and SUV mean was 1.07 to 21.47 and 0.91 to 14.69, respectively. Intraclass correlation coefficient between log of SUV max and log of SUV mean was 0.93 (95% confidence interval [CI], 0.88Y0.95) and 0.92 (95% CI, 0.87Y0.95), respectively.
Purpose: Measurement variance affects the clinical effectiveness of PET-based measurement as a semiquantitative imaging biomarker for cancer response in individual patients and for planning clinical trials. In this study, we measured test-retest reproducibility of SUV measurements under clinical practice conditions and recorded recognized deviations from protocol compliance. Methods: Instrument performance calibration, display, and analyses conformed to manufacture recommendations. Baseline clinical 18 F-FDG PET/CT examinations were performed and then repeated at 1 to 7 days. Intended scan initiation uptake period was to repeat the examinations at the same time for each study after injection of 12 mCi FDG tracer. Avidity of uptake was measured in 62 tumors in 21 patients as SUV for maximum voxel (SUV max ) and for a mean of sampled tumor voxels (SUV mean ). Results: The range of SUV max and SUV mean was 1.07 to 21.47 and 0.91 to 14.69, respectively. Intraclass correlation coefficient between log of SUV max and log of SUV mean was 0.93 (95% confidence interval [CI], 0.88Y0.95) and 0.92 (95% CI, 0.87Y0.95), respectively.
Correlation analysis failed to show an effect on uptake period variation on SUV measurements between the 2 examinations, suggesting additional sources of noise.
The threshold criteria for relative difference from baseline for the 95% CI were T49% or T44% for SUV max or SUV mean , respectively. Conclusions: Variance of SUV for FDG-PET/CT in current clinical practice in a single institution was greater than expected when compared with benchmarks reported under stringent efficacy study settings. Under comparable clinical practice conditions, interpretation of changes in tumor avidity in individuals and assumptions in planning clinical trials may be affected.
Key Words: FDG, PET, SUV, clinical effectiveness, test-retest reproducibility, external validity (Clin Nucl Med 2013;38: 175Y182) P ET using a glucose analog, 18 F-FDG, 1,2 integrated with CT (FDG-PET/CT), 3, 4 is useful 5 for metabolic 6 imaging in cancer. A quantitative avidity measurement for serial activity measurements 7Y11 of many cancer deposits potentially contributes a semiquantitative predictive or surrogate endpoint biomarker 12Y14 for cancer care.
The SUV, a semiquantitative measurement for tracer avidity on PET/CT, is widely available using commercial software available from manufacturers of imaging instrumentation. Although efficacy studies to measure variance of baseline SUV measurements are relatively few, with limited spectrum of cancers, preliminary recommendations for interpretive criteria have been published. In a landmark publication, Wahl et al 14 and expert collaborators have proposed the PERCIST 1.0 system as a working foundation to refine and validate quantitative approaches to monitoring FDG-PET tumor avidity response, integrated with anatomic measurements. They proposed preliminary interpretive criteria based on benchmark variance estimates derived from stringent study settings 15Y19 and on expert judgment derived from clinical experience. The proposed 30% threshold for a change for the FDG avidity index is subject to modification as future research may dictate. The authors emphasize the need for strictly reproduced technique. The European Organization for Research and Treatment of Cancer PET Study Group has recommended a 25% threshold. 19 A report on FDG-PET test-retest variance in cancer measurements in a multicenter study 20 showed thresholds for difference in baseline ranging from 32% to 52%. Limited analysis suggested that variance depended partly on compliance with protocols. Another report in nonYsmall cell lung cancer suggested a threshold of 37%. 21 The variance of SUV measurements not only affects individual patient management but also determines power in clinical trials. 22, 23 The present report extends work from 1 center contributing to the multicenter study, 20 including additional cases, more detailed analyses of sources of variance, discussion of the importance of the findings, and suggestions for process improvements.
PATIENTS AND METHODS
The institutional review board of the University of South Florida reviewed and approved the study protocol for retrospective review. Patients had received with 2 PET/CT examinations performed 1 to 7 days apart (median, 2 days; range 1Y7 days), just before phase I trials for therapy of resistant solid tumors: CA1820021 (4 patients) and CA182003 (17 patients); 11 women; 10 men (median age, 58 years; range, 42Y74 years) ( Table 1 ).
Imaging
Routine equipment performance verification steps complied with manufacturer instructions for calibration, attenuation correction, coincidences correction and detector variation correction, as well as image reconstruction including smoothing, decay correction, manual clock synchronization, and dose calibration. Quarterly procedures included multidimensional phantom image stability verification and well check, 12-hour normalization stability verification, and internal coincidence timing verification. Weekly automated checks include detector dead time, energy calibration, and amplifier gain. Daily automated checks include normalization, coincidence timing correction, tube warm-up, and CT calibration.
Examination protocols incorporated recommended standards. 24 Patients received oral and written instructions to follow a low carbohydrate diet during 3 days before examinations, avoid strenuous exercise within a day of examination, and fast for 6 hours before imaging. Patient compliance was not explicitly assessed. Blood glucose (BG) levels were measured before each tracer injection using reagent strips (Life Scan, Johnson and Johnson Company), with manufacturer's recommended controls.
Mean (SD) net dose injected was 12.2 (1.3) mCi of FDG (range, 9.6Y14.8 mCi) (451 [48] MBq; range, 355Y548 MBq). Dose remaining in syringe was subtracted; no adjustment was made for any extravasation. No gross extravasation was visually evident on images. During the uptake period, patients were semirecumbent and provided with warmed blankets if desired; oral hydration was encouraged. Initiation of scanning although targeted for a 90-minute uptake period after injection was initiated when the instrument became available in a busy clinical schedule, regardless of any delays.
Patients were scanned on the same Biograph PET system (Siemens Medical Solutions) or on a Discovery VCT PET/CT system (GE Medical Systems), except once when the original instrument was not available. Manual clock synchronization was used to correct for physical decay for uptake calculations. Each patient was scanned according to weight, for 2 to 5 minutes in each of 6 to 7 bed positions, from the base of skull through midthighs.
Acquisition conditions of the PET scanners were similar (FOV, 70 cm; matrix size, 128 Â 128; slice thickness, 3.3 mm; acquisition time, 21Y24 minutes; reconstruction method, iterative HD view point 20/2 iteration/subset, with #7 Gaussian smoothing filter). Display and analysis was on manufacturers' dedicated workstations. The Discovery VCT included a 64-slice CT scanner using row of 0 vertex, rotation time of 0.5 seconds per rotation, slice thickness of 3.75 mm, FOV of 50 to 70 mm, tube voltage of 120 kV, and tube electric current of 110 to 120 mA, with 64-slice acquisition technology. The Biograph acquisition technology was similar except using single slice CT technology. No enteric or IV contrast material was administered. Image acquisition was during quiet normal breathing. PET images were reconstructed using manufacturer's compensation for random coincidences, scattered radiation, and with CT-based attenuation correction.
Image Interpretation and Measurements
Images complied with Digital Imaging and Communication in Medicine format. 25 Transverse images with a slice thickness of 3.3 mm were reconstructed in multiple tomo-plane projections with variable window, level, PET-CT fusion control, and with 3-dimensional maximum intensity projection PET renditions. All images for each patient were analyzed at a single sitting by a single nuclear medicine physician (C.G.B.). Image processing software was ADW 4.2 for the Discovery VCT and Leonardo for the Biograph. For the selection of tumor volume, either 3 adjacent high-activity planes (17 patients) or a loosely fitting volume of interest was manually positioned after examination in multiple projections. SUVs were calculated using the maximum voxel (SUV max ) and the average voxel (SUV mean ) within the region of interest drawn around each tumor using 42% or more of the maximum voxel as the sampled volume with visual exclusion of nontumor structures (for SUV formulas, see Appendix E-I online). Additional analyses included effect of normalization for body surface area, 26 lean body mass (LBM), 26 and for cerebellum and liver reference tissue. For cerebellum, SUVs were measured centered on an axial plane with highest radioactivity; for the normal liver parenchyma; SUVs were measured in the right lobe at the level of the right portal vein. All available original data entries were included in analyses.
Statistical Analyses
The difference for a continuous variable measured at 2 separate examinations was evaluated by the Wilcoxon signed rank test. The correlation between 2 measurements was calculated by Spearman correlation coefficient. SUV data did not meet the normality assumption; log-transformation was taken. 27 Intraclass correlation coefficient (ICC) was used to assess test-retest reproducibility. Analysis-of-variance estimator was used for estimating ICC, and its 95% confidence interval (CI) was calculated by F statistics with correlation characterized as poor (ICC, 0Y4), fair to good (ICC, 0.4Y0.75), and excellent (ICC, 0.75Y1). 28 The percentage of relative difference between the repeated SUV measurements (defined by
The limits of agreement were calculated by RD T 2 Â SE (RD), and these were used for threshold for relative difference of SUV measurements, where RD is average of RD and SE (RD) is the standard error of RD. 29 Statistical analysis was carried out using SAS 9.2 (SAS Inc, Cary, NC) and MATLAB (MathWorks, Natick, MA). Table 2 shows weight and BG; the median difference in patient weight between the scans was 0 kg (range, j2 to 2.5 kg; P = 0.87). The median difference in BG concentrations was 3 mg/dL (range, j16 to 72 mg/dL; P = 0.08).
The tracer uptake period was 106 T 30 minutes for the baseline examination and 113 T 26 minutes for the follow-up (Table 2) , with a distribution of uptake periods corresponding to SUV max as shown in Figure 1 .
Correlation analyses, shown in Figure 2 disclosed no dependence of log SUV max or log SUV mean upon the difference in uptake period: The absolute difference in SUVs (raw data and after taking log transformation) was independent of the absolute difference in uptake period (raw data: r = 0.034, P = 0.794 and r = j0.136, P = 0.292; after log-transformation: r = j0.01, P = 0.936 and r = j0.126 with P = 0.329 for SUV max and SUV mean , respectively). Among all patients, the range of SUV max and SUV mean were 1.07 to 21.47 and 0.91 to 14.69, respectively.
The difference in each of SUV measure was not normally distributed (both P G 0.005), and the difference in SUV values increased with their average on a Bland-Altman plot (Figs. 3A, B) . However, the difference between log of the values was normally distributed for both of SUVs (P 9 0.25 for SUV max and P = 0.10 for SUV mean ). The Spearman correlation coefficient (r) between SUV max and SUV mean determined on the 2 separate occasions was 0.933 (P G 0.001) and 0.925 (P G 0.001), respectively. ICC between log of SUV max and log of SUV mean was 0.926 (95% CI, 0.880Y0.954) and 0.920 (95% CI, 0.871Y0.951), respectively (Figs. 3C, D). Thus, both log measures showed ''excellent'' test-retest reproducibility according to a statistical benchmark definition applied to ICC. 30 The median of difference for SUV max and SUV mean were j0.22 (range, j4.40 to 7.77; P = 0.69) and j0.08 (range, j2.45 to 4.79; P = 0.09).
To address the question of threshold criteria for a difference from baseline SUV measurement, Bland-Altman plots on which the relative difference between 2 SUV max and SUV mean are plotted against the mean of 2 measurements. The threshold criteria for a difference from baseline for the 95% CI were T49% or T44% for SUV max or SUV mean , respectively (Fig. 4) .
The possibility to reduce noise of avidity measurements by normalization to normal liver or cerebellum was evaluated. Correlations of tumor SUVs with cerebellar and liver SUVs are depicted in Figure 4 . SUVs normalized to cerebellar SUV were highly correlated (r = 0.903 with P G 0.001 and 0.922 with P G 0.001 for SUV max and SUV mean , respectively). For log of SUVs normalized to cerebellar SUV (ICC of 0.924 with 95% CI of 0.877Y0.953 and 0.927 with 95% CI of 0.882Y0.955 for SUV max and SUV mean , respectively), the reproducibility was excellent. The Bland-Altman plot showed agreement for log of SUV max (median difference, j0.01; range, j0.48 to 0.40; P = 0.186) and for SUV mean (median difference, j0.01; range, -j0.52 to 0.35; P = 0.134). SUV values normalized to liver SUV showed excellent correlation (r = 0.913 and 0.910 for SUV max and SUV mean , respectively; all P's G 0.001), and correlation of log of SUV max normalized to liver SUV showed excellent reproducibility (ICC, 0.921; 95% CI, 0.872Y952). However, ICC for log of SUV mean normalized to liver SUV was not excellent (ICC, 0.702; 95% CI, 0.551Y0.809). Thus, normalization to liver and cerebellum activity correlations did not suggest an independent potential approach to reducing variance. The limitations of normalization to liver or cerebellum may be due to biological limitations. Because SUVs in normal tissue are neither stable nor consistently related to tumor uptake with time, 10, 31 variations in the uptake period in the current series could overwhelm any potential value of normalization. More consistent protocol compliance might show value of normalization. 32 We found no correlation in BG change or elevation and change in SUV (Fig. 5) . Normalization for LBM and body surface area, as expected, did not reduce variance during the short interval of this work (data not shown) but could be important in longitudinal studies.
DISCUSSION
The potential value of quantitation in PET imaging is highest if the measurement variance is small. The current work addresses the clinical effectiveness of SUV measurement, compared with the benchmark for variance based on stringent efficacy trials and recommended by experts. Wahl et al 14 propose for the PERCIST 1.0 standard that includes preliminary significance threshold recommendation for interpretation of differences in avidity indices. Although some stringent efficacy trials showed mean reproducibility within 10% to 20%, 15, 18, 33 they suggested a threshold of 30% for a significant avidity index difference. For this recommendation, they considered not only efficacy trial results but variations in technology and their clinical experience. They also recommended technical refinements to reduce effects of pixel noise, reproduction of uptake periods within 15 minutes, and other refinements. Software to fully implement the suggestions of Wahl et al is not widely available. In our series, using manufacturers' equipment performance calibration and widely available commercial software and our actual routine clinical practices, the threshold for a significance difference seems closer to 50%.
Several possible causes of noise in the measurements warrant discussion. Deviation from targeted uptake times is a well-known cause of variation in avidity. 18, 20, 34 FDG uptake in lung carcinoma, for example, does not plateau for several hours, 31, 35, 36 so variation in uptake period should cause variation in SUV. Weber 37 recommends repeating uptake periods within 10 minutes, cautioning that ''Iin clinical practice this requires careful planning of the time of FDG injection and start of scanning.'' Interactive scheduling software and more flexible dispensing systems may improve compliance with uptake period targets, in addition to that achievable by greater emphasis on compliance. Automated calculation and reporting of uptake periods could also be incorporated into equipment software. However, the present study could not show a correlation between our considerable uptake period deviations and measurement variation, when evaluated over the full range of data. We therefore suspect additional sources of measurement noise.
Variance and bias in SUV measurements may also be due to instrument performance changes, execution, and interpretation of the examination or biological change in the patient.
Although equipment performance can be verified by measures similar to ours, 38 further improvement is possible at minimal cost. 39 Multicenter standardization efforts may open approaches to improvement, intrainstitution and interinstitution. 11,40Y44 Approximately 8 technical steps entail risk of error (C Kuykendall, CNMT 2011, personal communication): performance and recording of dose calibration, clock synchronization, accounting for tracer not available for uptake, several scanners set-up steps, weight recording, and patient identification are among potentially significant sources of variation. Application of well-established quality improvement technology may minimize opportunity for technical error: technical performance of PET/CT resembles that of other industrial processes for which a recent Radiological Society of North America initiative formulates process improvements adapted for imaging departments. 44Y46 Automation by improvements through interoperability software may eliminate manual data transfer; improved operator interfaces may simplify technical processes and reduce error. Improved training, cross-training, continued sharing of performance measures, and management support for the process are among the key elements of the methodology.
For biological standardization, fasting diet is recommended in standard FDG-PET/CT guidelines. 24, 47 Diet compliance is difficult to evaluate. BG sometimes is elevated in our population; a suggestion excluding patients with BG of 7 mmol/L of greater (or 9120 mg/dL) 47 would have excluding 3 of our patients. Any criteria that exclude patients from testing should be carefully justified; however, improved patient preparation education would pose little burden.
Although the SUV max is more subject to noise compared with SUV mean , SUV max and SUV mean showed minimal difference in variance in our results. Although there are sound reasons to consider other variations of uptake measurement, 14, 48 we confined our analyses to measurements supported by readily available software.
Variance is important not only in individual patient measurements but also in clinical trial design, as a component of total noise effect on the power of clinical trials 22, 49 : underestimation of variance may lead to underpowered clinical trials, obscuring important effects.
These results emphasize that other tumor markers including anatomic measurements from CT, despite limitations as an indicator of cancer biology, remain useful. 50Y52 Anatomic measures should be continued as a reference standard for longitudinal studies.
Costs, including patient convenience, radiation exposure, and other costs discourage repeat of recent PET/CT examinations solely to establish a baseline for serial comparisons, even when baseline studies and longitudinal studies are from different institutions. A phantom examination evaluation of variability in PET quantization within a multicenter consortium 53 showed SUV variability of 10% to 25%. Large-scale efforts are underway to harmonize technology. 11, 40 Meanwhile, caution is warranted in interpretation of quantitative changes in PET avidity for clinical decisions even from a single institution. 54 The distinction 55 between questions of efficacy (''Can intervention work in the ideal study setting?'') and effectiveness (''Does it work, generalized to real-world settings and applied to individual patients?'') parallels discussions of generalization of trial results, ''external validity,'' (suitability of translating clinical procedures established in stringent trials to widespread clinical practice use). 56, 57 The present work emphasizes that interpretive criteria derived from efficacy studies may not be applicable to effectiveness studies.
Limitations
In common with all earlier publications in this field, the tumor spectrum and relatively small numbers of patients and cancers investigated limit extrapolation of the current results. Different cancers, even within the same cell type, may differ in optimum imaging times under clinical conditions, and variance and optimal uptake periods may differ. 58 Data from the longer uptake periods used are not directly applicable for the more generally used target of 60 minutes. 41 Technical staff was not blinded to the nature of the research. Use of a single, highly experienced observer reflects an actual clinical practice, but the result could differ for other observers.
Baseline test-retest data do not necessarily predict variance in serial studies. For longitudinal studies, partial volume effects, 59 tumor heterogeneity, tumor size effects, and spillover from adjacent structures may change and further contribute to bias and variance. Normalization to LBM could be important during the course of serial examinations. Important factors may include cell type, tumor avidity and size, other phenotypic information, treatment effectiveness, alternatives available, and clinical judgment. 60 Indices of dose extravasation and other factitious redistribution should be validated.
Variance other than at baseline must be studied to refine interpretive criteria. Although refined criteria for significant change may improve FDG-PET quantitation, the value of the technology ultimately depends on additional research to show correlation with clinical outcomes.
CONCLUSIONS
Test-retest measurements of SUV from FDG PET baseline examinations under clinical conditions suggest thresholds for agreement approaching 50%, using a relative difference approach, for a high level of confidence. Although methods and expressions of criteria differ, this threshold is higher than expert recommendations derived from stringent efficacy trials, although actual trial conditions are often not fully described.
We suggest: (1) The interpretation of SUV results in individual patients and planning for clinical trials should consider the variance expected under the actual imaging conditions, not necessarily equivalent to those of stringent efficacy trials. (2) Clinical practice of PET/CT should strive to more nearly approach the benchmarks set by stringent trials. 
